DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
CYRX logo

Cryoport, Inc. Stock Price

NasdaqCM:CYRX Community·US$783.5m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 5 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

CYRX Share Price Performance

US$15.14
5.55 (57.87%)
​
US$19.33
Fair Value
US$15.14
5.55 (57.87%)
21.7% undervalued intrinsic discount
US$19.33
Fair Value
Price US$15.14
AnalystConsensusTarget US$19.33
AnalystLowTarget US$15.00
AnalystHighTarget US$25.00
Sun, 23 Aug 26
Fair ValueUS$19.33
Share Pricen/a

CYRX Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$19.33 21.7% undervalued intrinsic discount

Cold Chain Expansion Will Support Cell And Gene Therapies

0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value US$15 Fairly Valued intrinsic discount

Rising Biopharma Regulations Will Crimp Expansion But Foster Recovery

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value US$25 39.4% undervalued intrinsic discount

Digitalization And Secular Trends Will Expand Biotech Cold Chain Services

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
CYRX logo
Cryoport
21.7% undervalued intrinsic discount

Cold Chain Expansion Will Support Cell And Gene Therapies

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 23 Aug
Read Narrative
CYRX logo
Cryoport
39.4% undervalued intrinsic discount
Updated

Digitalization And Secular Trends Will Expand Biotech Cold Chain Services

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 6 Sep
Read Narrative
CYRX logo
Cryoport
Fairly Valued intrinsic discount

Rising Biopharma Regulations Will Crimp Expansion But Foster Recovery

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 9 Aug
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystHighTarget
CYRX logo

CYRX: Rebounding Cell And Gene Therapy Demand Will Drive Future Upside

Fair Value: US$25 39.4% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
CYRX logo

CYRX: Cell And Gene Recovery And Bioservices Edge Will Support Future Repricing

Fair Value: US$19.33 21.7% undervalued intrinsic discount
4 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystLowTarget
CYRX logo

CYRX: Cell And Gene Therapy Recovery Will Test Service Margin Resilience

Fair Value: US$15 Fairly Valued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Adequate balance sheet and fair value.

1 Risk
1 Reward
View Full Analysis

Cryoport, Inc. Key Details

US$186.5m

Revenue

US$98.7m

Cost of Revenue

US$87.8m

Gross Profit

US$128.7m

Other Expenses

-US$40.9m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
-0.81
47.08%
-21.94%
38.1%
View Full Analysis

About CYRX

Founded
1999
Employees
688
CEO
Jerrell Shelton
WebsiteView website
www.cryoportinc.com

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company’s Life Sciences Services segment provides temperature-controlled logistics and biostorage, bioservices and cryopreservation services within the life science industry. Its Life Sciences Products segment manufactures, and sells cryogenic freezers, cryogenic dewars, and related ancillary accessories within the life science industry through direct sales or a distribution network. The company’s products include Cryoport Express Shippers; Cryoport Elite; Cryoport Express Cryogenic HV3 Shipping System; Smartpak Condition Monitoring System and Tec4Med, an IoT-based monitoring solutions; and Cryoport accessories. It also provides Cryoport BioStorage/Bioservices, such as Cryoport Systems Bioservices, including controlled temperature storage, kitting, labelling, fulfillment, sample management, drug return, and Qualified Person drug product release. In addition, the company offers IntegriCell services that comprise apheresis/leukapheresis collection, cryoshuttle transportation, cryo-process optimization, and cryopreservation services; Cryoport consulting services; MVE Fusion cryogenic system, a self-sustaining cryogenic freezer; and MVE Vario cryogenic system, a cryogenic freezer system. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. The company was founded in 1999 and is based in Brentwood, Tennessee.

Recent CYRX News & Updates

User avatar
Narrative Update • Sep 06

CYRX: Rebounding Cell And Gene Therapy Demand Will Drive Future Upside

Analysts have lifted their Cryoport fair value estimate to $25 from about $19.93, pointing to higher price targets across the Street. They cite recovering Cell and Gene Therapy markets, healthier growth in MVE, and high teens growth in the BioLogistics and BioStorage divisions as key supports for the new view.
User avatar
Narrative Update • Aug 23

CYRX: Cell And Gene Recovery And Bioservices Edge Will Support Future Repricing

Analysts have raised their blended price target for Cryoport to about $19.33 from roughly $17.06, citing updated views on revenue growth, profit margins, and future P/E, following a series of Street target increases ranging from $13.50 to $25. Analyst Commentary Recent Street research on Cryoport points to a more constructive tone on the stock, with several bullish analysts lifting price targets after revisiting their views on the company’s growth drivers and execution in core segments like Cell and Gene Therapy logistics and bioservices.

Recent updates

No updates

Cryoport, Inc. Competitors

CLDX logo

Celldex Therapeutics

Symbol: NasdaqCM:CLDX
Market cap: US$3.1b
ARQT logo

Arcutis Biotherapeutics

Symbol: NasdaqGS:ARQT
Market cap: US$3.1b
NAMS logo

NewAmsterdam Pharma

Symbol: NasdaqGM:NAMS
Market cap: US$3.1b
IMNM logo

Immunome

Symbol: NasdaqCM:IMNM
Market cap: US$3.0b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide